Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology anda non-exclusive license for AsCas12a Shoreline to acquire Editas Medicines iNK cell franchise, including EDIT-202 and certain ...

Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK programs Mark S. Shearman, Ph.D., Chief Scientific Officer to step down, departing March 31 ...

ProKidney (NASDAQ:PROK Get Rating) and Editas Medicine (NASDAQ:EDIT Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, ...

Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) has been assigned an average recommendation of Hold from the thirteen brokerages that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating ...

Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Latest Ratings for ...